LRP4 (LDL Receptor Related Protein 4)

P1, N=0, Withdrawn, Nanjing Bioheng Biotech Co., Ltd. | N=18 --> 0 | Not yet recruiting --> Withdrawn

The TLR4-NLRP4 axis is a context-dependent regulator of gut and systemic immunity. Targeted modulation of this pathway represents a promising strategy to restore immune homeostasis while preserving host defense, supporting its relevance as a translational therapeutic target across multiple immune-mediated disorders.

This study confirmed the validity of the cyclophosphamide-busulfan induced mouse model of ovarian senescence, highlighted both the shared and distinct molecular mechanisms of physiological and pathological ovarian aging, and identified promising early biomarkers and therapeutic intervention targets.

P1, N=36, Not yet recruiting, Dongguan Taixin Hospital; Dongguan Taixin Hospital

All three aforementioned genes may be associated with the responsiveness of malignant human B-cell Lines to R-CHOP therapeutic agents. These results demonstrated that 19-GPS signature was effective and might potentially assist in guiding the prognosis and treatment options for DLBCL.

The evolving landscape of gMG treatment reflects a shift toward immunopathology-based precision medicine. Better characterization of subtype-specific molecular signatures and immune dysfunctions is essential to guide clinical decision-making and improve outcomes for treatment-refractory patients.

We further demonstrate that overexpression of LRP4 is common in residual disease post-treatment and is associated with breast tumors of poor prognosis. This work has demonstrated that the LRP4/YAP axis drives radioresistance by promoting the emergence of RTP cells through radiation-induced plasticity, and that modulation of the LRP4/YAP axis is a promising strategy for sensitizing breast cancers to radiotherapy, opening up a new avenue for improving patient outcomes.

We review the evolution of diagnostic assays, from early RIA to modern CBA, and addresses interpretative pitfalls, particularly in borderline or "seronegative" cases. Finally, the authors address the significance of accurate autoantibody detection in the diagnosis and management of patients with one of the antibody MG subtypes, as well as in patients with other autoimmune conditions and thymic malignancies.

Due to the variable presentation of symptoms, diagnosing MG can be challenging. A comprehensive approach that combines clinical assessment, serological testing, electrophysiological studies, and imaging is essential for accurate diagnosis.

The patient regained mobility and has sustained remission during short-term follow-up. This case highlights the therapeutic potential of teclistamab and BCMA-targeting strategies in MG, warranting further investigation.

P=N/A, N=60, Completed, Affiliated Hospital of Zunyi Medical University; Affiliated Hospital of Zunyi Medical University

Our research suggests that periplocin may serve as a promising treatment for IVDD, offering anti-inflammatory benefits, preventing ECM degradation, and promoting ECM anabolism.